Karvidil (Carvedilol)

Carvedilol blocks β1, β2 and α1 adrenergic receptors. β‑blockade slows heart rate and reduces myocardial contractility, while α1‑blockade causes vasodilation. The combined effect lowers peripheral vascular resistance and blood pressure, and improves overall cardiac efficiency.

The dose of Karvidil is individualized by the prescribing clinician based on the patient’s condition, response, and tolerance. Dosage adjustments are typically made gradually to achieve target blood pressure or heart‑failure goals while minimizing side effects.

Safety data for carvedilol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Karvidil product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike cardio‑selective agents such as metoprolol, carvedilol blocks both β‑receptors and α1 receptors, offering additional vasodilatory effects. This broader profile can provide greater blood‑pressure reduction and may be advantageous in heart‑failure patients, but it may also increase the likelihood of certain side effects like dizziness or peripheral edema.

Karvidil should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency.

Karvidil is taken orally, usually with food to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a full glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include bronchospasm in patients with reactive airway disease, severe bradycardia or heart block, and hepatic dysfunction. Patients should be monitored for signs of respiratory distress, markedly slow heart rate, or abnormal liver function tests during therapy.

Karvidil is contraindicated in individuals with known hypersensitivity to carvedilol, severe bradycardia, second‑ or third‑degree AV block without a pacemaker, decompensated heart failure, and uncontrolled asthma or COPD. Clinicians should also exercise caution in patients with significant liver disease.